(81 days)
The CELL-DYN® 3000 Series are automated, multi-parameter hematology analyzers intended for in-vitro diagnostic use in the Clinical Laboratory and the Physician's Office Laboratory (POL).
The Cell-Dyn® 3000 Series instruments process human whole blood specimens to provide a hemogram with automated differential.
The CELL-DYN® 3000 Series instruments each consist of three major modules: the Analyzer, which aspirates, dilutes and analyzes each whole blood specimen; the Data Station/Module, which controls all system processing and provides the primary operator interface with the system; and the Printer, which generates reports automatically or on demand.
The CELL-DYN® 3000 Series instruments are designed to analyze K3EDTA anticoagulated human whole blood specimens and report the hematological parameters shown in the table on the following page:
Reported Parameters: White Blood Cell Parameters (WBC, NEU, %N, LYM, %L, MONO, %M, EOS, %E, BASO, %B), Red Blood Cell Parameters (RBC, HCT, MCV, RDW, RETC (CELL-DYN 3500R only), MCH, MCHC), Platelet Parameters (PLT, MPV, *PDW, *PCT), Hemoglobin Parameters (HGB). * These parameters are provided for laboratory use only and are not reportable in the US.
This document describes a 510(k) submission to expand the intended use of the Abbott CELL-DYN® 3000 Series Hematology Systems to include Physician's Office Laboratories (POLs). The submission focuses on demonstrating the substantial equivalence of these devices for use in POLs.
1. Table of Acceptance Criteria and Reported Device Performance:
The document doesn't explicitly define numerical acceptance criteria in a table format. Instead, it states that "Accuracy, precision, and linearity data show performance to manufacturer's specifications." The study aims to demonstrate equivalence, implying that the performance of the CELL-DYN® 3200 in a POL setting meets the established performance of the CELL-DYN® 3500R and CELL-DYN® 3000, which are already cleared for clinical laboratory use.
The reported device performance is described as demonstrating "equivalence" between the CELL-DYN® 3200 System and the CELL-DYN® 3500R System for the following measured parameters:
| Parameter | Reported Performance |
|---|---|
| White Blood Count (WBC) | Equivalence to CELL-DYN® 3500R and manufacturer's specifications |
| WBC differential sub populations | Equivalence to CELL-DYN® 3500R and manufacturer's specifications |
| Red Blood Count (RBC) | Equivalence to CELL-DYN® 3500R and manufacturer's specifications |
| Hemoglobin concentration (HGB) | Equivalence to CELL-DYN® 3500R and manufacturer's specifications |
| Mean Corpuscular Volume (MCV) | Equivalence to CELL-DYN® 3500R and manufacturer's specifications |
| Red Cell Distribution Width (RDW) | Equivalence to CELL-DYN® 3500R and manufacturer's specifications |
| Platelet Count (PLT) | Equivalence to CELL-DYN® 3500R and manufacturer's specifications |
| Mean Platelet Volume (MPV) | Equivalence to CELL-DYN® 3500R and manufacturer's specifications |
2. Sample Size Used for the Test Set and Data Provenance:
The document does not explicitly state the sample size used for the test set or the data provenance (e.g., country of origin, retrospective/prospective). It generally refers to "the data compiled to support the claim" and "accuracy, precision, and linearity data."
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of those Experts:
This information is not provided in the document. The study focuses on demonstrating analytical performance equivalence between automated hematology analyzers, not on expert interpretation of results.
4. Adjudication Method for the Test Set:
This information is not provided. Given the nature of the device (automated hematology analyzer), human adjudication of ground truth in the traditional sense is unlikely to be a primary method for establishing analytical performance.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done:
No, an MRMC comparative effectiveness study was not done. This type of study is more relevant for diagnostic devices that involve human interpretation of images or other subjective data. This submission is for an automated hematology analyzer assessing analytical performance.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was done:
Yes, the studies described are inherently standalone performance evaluations. The CELL-DYN® 3000 Series are automated instruments. The equivalency data for background, accuracy, precision, linearity, and carryover are all measures of the algorithm's (device's) analytical performance independent of human intervention in the result generation.
7. The Type of Ground Truth Used:
The ground truth for this type of analytical device would typically be established through:
- Reference Methods: Using established, highly accurate reference methods for each hematological parameter.
- Calibrators and Controls: Utilizing commercially available or in-house manufactured calibrators and controls with known values.
- Inter-instrument Comparison: Comparing results to a legally marketed predicate device (in this case, the CELL-DYN® 3500R) that has already proven accurate performance.
The document states that "Equivalence is demonstrated between the CELL-DYN® 3200 System and the CELL-DYN® 3500R System," suggesting the latter served as a reference or "ground truth" for the comparison of analytical performance.
8. The Sample Size for the Training Set:
This information is not provided. The document describes a 510(k) submission for expanding the intended use of existing devices, not the development or training of a new algorithm. Therefore, "training set" in the context of machine learning is not directly applicable here. The devices are based on established principles of operation (flow cytometry, laser optical scatter, impedance, optical absorbance) rather than machine learning models that require explicit training sets.
9. How the Ground Truth for the Training Set was Established:
As mentioned above, the concept of a "training set" in the machine learning sense is not applicable to this submission. The devices operate based on physical principles of cell analysis. The "ground truth" for the initial development and calibration of these instruments would have been established through rigorous analytical validation using reference methods, calibrators, and known clinical samples.
{0}------------------------------------------------
AFR 2 4 1998
CELL-DYN 3000 Series Hematology Systems
510(k) Supplement
510(k) SUMMARY CELL-DYN® 3000 Series Hematology Systems POL Supplement
510(k) Summary of Safety and Effectiveness Information Supporting a Substantially Equivalent Determination
The following information as presented in the 510(k) Supplement to Expand the Intended Use for Physician's Office Laboratories (POLs) for the Abbott CELL-DYN®3200 (K972354), the CELL-DYN® 3500R (K960427) and the CELL-DYN® 3000 (K955673) Systems constitutes data supporting a substantially equivalent determination. These three systems are referred to as the CELL-DYN® 3000 Series. The methods of determination while operated in POLs are those used by the CELL-DYN® 3000 Series.
Intended Use
The CELL-DYN® 3000 Series are automated, multi-parameter hematology analyzers intended for in-vitro diagnostic use in the Clinical Laboratory and the Physician's Office Laboratory (POL).
Device Description
The CELL-DYN® 3000 Series instruments each consist of three major modules: the Analyzer, which aspirates, dilutes and analyzes each whole blood specimen; the Data Station/Module, which controls all system processing and provides the primary operator interface with the system; and the Printer, which generates reports automatically or on demand.
The CELL-DYN® 3000 Series instruments are designed to analyze K3EDTA anticoagulated human whole blood specimens and report the hematological parameters shown in the table on the following page:
{1}------------------------------------------------
Reported Parameters
| White Blood Cell Parameters: | Red Blood Cell Parameters: |
|---|---|
| WBC -- White Blood Cell or leukocyte Count | RBC -- Red Blood Cell or erythrocyte count |
| NEU -- Neutrophil absolute count | HCT -- Hematocrit |
| %N -- Neutrophil percent | MCV -- Mean Corpuscular Volume |
| LYM -- Lymphocyte absolute count | RDW -- Red Cell Distribution Width |
| %L -- Lymphocyte percent | RETC -- Reticulocytes (CELL-DYN 3500R only) |
| MONO -- Monocyte absolute count | MCH -- Mean Corpuscular Hemoglobin |
| %M -- Monocyte percent | MCHC -- Mean Corpuscular HemoglobinConcentration |
| EOS -- Eosinophil absolute count | |
| %E -- Eosinophil percent | Platelet Parameters: |
| BASO -- Basophil absolute count | PLT -- Platelet Count |
| %B -- Basophil percent | MPV -- Mean Platelet Volume |
| Hemoglobin Parameters: | *PDW -- Platelet Distribution Width |
| HGB -- Hemoglobin concentration | *PCT -- Plateletcrit |
- These parameters are provided for laboratory use only and are not reportable in the US.
Principles of Operation:
The Cell-Dyn® 3000 series count, size and classify blood cells by a combination of methods: flow cytometry laser optical scatter and/or impedance. The instruments use a Helium-Neon laser as the optical light source. The Optical Bench detects light in the form of scatter from blood cell surfaces and internal structures.
For the WBC parameters, whole blood is diluted with a reagent to preserve cell integrity. Data are simultaneously collected for four angles (0°, 10°, 90°, and 90°D) of light scatter as . each cell passes through the laser beam. For the RBC and PLT parameters, whole blood is diluted with a reagent that prepares the cells for measurement. The dilution is split and measured by laser optical scatter at (0° and 10°) or impedance.
For the hemoglobin parameter, whole blood is diluted with a cyanide free and/or cyanide containing reagent and the hemoglobin is measured optically by absorbance at 540nm.
Similarities and Differences:
The CELL-DYN® 3000 Series instruments are all similar in that they utilize Optical Laser Light Scatter from a Helium neon Laser to count and differentiate WBCs, they use anticoagulated human whole blood specimens, they automatically dilute and aspirate specimens, and specimens may be run using automated specimen processing. All count fragile WBCs, all have extended counts for WBCs and PLTs, all measure Hemoglobin by Optical Absorbance and all have internal Quality Control programs.
{2}------------------------------------------------
The CELL-DYN® 3000 Series are different in that the CELL-DYN® 3500R and the CELL-DYN® 3000 utilize impedance for counting and sizing RBCs and PLTs, while the CELL-DYN® 3200 utilizes Optical Light Scatter. Only the CELL-DYN® 3500R has the capability of counting and reporting Reticulocyte results.
Equivalency Data:
The data compiled to support the claim that the CELL-DYN® 3200 System is substantially equivalent when used in a POL to the other CELL-DYN® 3000 series instruments includes background, accuracy, precision, linearity, and carryover. Equivalence is demonstrated between the CELL-DYN® 3200 System and the CELL-DYN® 3500R System for the following measured parameters: White Blood Count (WBC), WBC differential sub populations. Red Blood Count (RBC). Hemoglobin concentration (HGB), Mean Corpuscular Volume (MCV), Red Cell Distribution Width (RDW), Platelet Count (PLT) and Mean Platelet Volume (MPV). Accuracy, precision, and linearity data show performance to manufacturer's specifications.
Conclusion:
There are more similarities between the CELL-DYN® 3000 Series of instruments than there are differences. Demonstration of the equivalence of the CELL-DYN® 3200 data to the CELL-DYN® 3500R and the similarities of the CELL-DYN® 3000 Series, provides the validation for an extension of the Intended Use to include Physician's Office Laboratories (POLs).
{3}------------------------------------------------
DEPARTMENT OF HEALTH & HUMAN SERVICES
2098 Gaither Road Rockville MD 20850
Food and Drug Administration
Image /page/3/Picture/2 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized graphic of three human profiles facing right, stacked on top of each other. The profiles are black and have a curved, flowing design. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" is arranged in a circular pattern around the graphic.
APR 2 4 1998
Ms. Janice E. Brown Requlatory Affairs Manager Abbott Laboratories Diaqnostics Division 5440 Patrick Henry Drive Santa Clara, California 95054
Re : K980614
Trade Name: Abbott Laboratories CELL-DYN® 3000 Series Hematology Systems Regulatory Class: II Product Code: GKZ Dated: January 30, 1998 Received: February 2, 1998
Dear Ms. Brown:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the qeneral controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labelinq, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth. in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal Laws or Requlations.
{4}------------------------------------------------
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770)488-7655.
This letter will allow you to begin marketing your device as described in your 510 (k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number (800) 638-2041 or at (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html"
Sincerely yours,
Steven Butman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure .... ... ...........................................................................................................................................................
{5}------------------------------------------------
510(k) Number (if known): CELL-DYN® 3200 System (K972354) CELL-DYN® 3500R (K960427) CELL-DYN® 3000 (K955673).
Device Name:
CELL-DYN® 3000 Series of Instruments
Intended Use:
The Cell-Dyn® 3000 Series instruments are automated hematology analyzers intended for in-vitro diagnostic use in the clinical laboratory and the Physician's Office Laboratory (POL).
Indications For Use:
The Cell-Dyn® 3000 Series instruments process human whole blood specimens to provide a hemogram with automated differential.
Ree E. Matin
Prescription doc
§ 864.5220 Automated differential cell counter.
(a)
Identification. An automated differential cell counter is a device used to identify one or more of the formed elements of the blood. The device may also have the capability to flag, count, or classify immature or abnormal hematopoietic cells of the blood, bone marrow, or other body fluids. These devices may combine an electronic particle counting method, optical method, or a flow cytometric method utilizing monoclonal CD (cluster designation) markers. The device includes accessory CD markers.(b)
Classification. Class II (special controls). The special control for this device is the FDA document entitled “Class II Special Controls Guidance Document: Premarket Notifications for Automated Differential Cell Counters for Immature or Abnormal Blood Cells; Final Guidance for Industry and FDA.”